System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Parakkal Deepak is an expert in Gastroenterology at Washington University Medical Center (United States). As of October 2026, ScienceLeadR ranks Parakkal Deepak in the top 1% of experts worldwide for Crohn Disease, Inflammatory Bowel Diseases and Gastroenteritis. Parakkal Deepak has authored 399 publications, the most recent in 2026, and is an investigator in 15 clinical trials, 9 of them ongoing. SLR score: 2,029 (community average: 125). How the SLR is computed.

LeadR Profile

Parakkal Deepak Washington University Medical Center United States
2 029 ScienceLeadR Reputation 2029

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Hepatology - Medical Imaging - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2008 - 2026
Source: PubMed

Washington University in St. Louis

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 399

Citations

Citations: 4 784 1st author: 68 Last author: 135 Unique author: 2

Main journals

Gastroenterology 138
Am J Gastroenterol 51
J Crohns Colitis 31
Inflamm Bowel Dis 25
Clin Gastroenterol Hepatol 20

Best Journals

Gastroenterology 11
Lancet Gastroenterol Hepatol 3
Ann Intern Med 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The rise of reducing reagent-resistant TfR1 dimer marks ferroptosis.
PMID 42907496 — cells, ferroptosis, cell biology		Nat Cell Biol20260
The role of glucagon-like peptide 1 receptor agonists in the management of patients with inflammatory bowel diseases.
PMID 42593078 — glucagon-like peptide 1, comorbidity, glucagon-like peptide-1 receptor, crohn disease, inflammatory bowel diseases, obesity, glucagon, therapeutics, metabolic syndrome, colitis, ulcerative, glucagon-like peptides		Inflamm Bowel Dis20260
Performance of Google NotebookLM for AI-assisted data extraction and consensus statement generation in a heterogenous systematic review on inflammatory bowel disease, obesity, and cardiometabolic comorbidities: A Methodological Report.
PMID 42396330 — cells, comorbidity, workflow, inflammatory bowel diseases, obesity, artificial intelligence		medRxiv20261
Novel mouse models for perianal fistulizing Crohn's disease reveal therapeutic value of interferon-γ antagonists.
PMID 42327245 — interferon-gamma, flow cytometry, fistula, crohn disease, therapeutics, tissues		bioRxiv20260
Impact of Crohn's perianal fistulas on healthcare resource utilization: a US chart review study.
PMID 42267525 — fistula, multiple chronic conditions, therapeutics, outpatients		J Med Econ20260

Clinical Studies 15

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 11

By phase:

Phase 4 5
Phase 3 4
N/A 3
Phase 1 1
Phase 1/Phase 2 1
Phase 2 1

By status:

Recruiting 6
Active not recruiting 2
Completed 2
Not yet recruiting 2
Terminated 2
Unknown 1

By type:

Interventional 12
Observational 3

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 3
multicentric5to9 4
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 3

Ongoing Clinical Trials

9 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
MIRICURE Mirikizumab With Curettage and Repair (Closure) for Perianal Fistulizing Crohn s Disease
NCT07782021 — injections, interleukin-23, anesthesia, curettage, fistula, crohn disease, magnetic resonance imaging, maintenance, therapeutics, infusions, intravenous		Phase 4Not yet recruiting2026
Tirzepatide for Ileal Pouch anal Anastomosis (IPAA) and Chronic High Bowel Frequency (I8F NS X008)
NCT07756359 — glucagon-like peptide 1, glucagon-like peptide-1 receptor, loperamide, pharmaceutical preparations, drug combinations, proctocolectomy, restorative, inflammatory bowel diseases, diphenoxylate, therapeutics, atropine		Phase 4Not yet recruiting2026
Moving Beyond Inflammation as a Therapeutic Target for Crohn s Disease
NCT06976853 — intestines, crohn disease, research, therapeutics, biological therapy, colonoscopy		Phase 2Recruiting2025
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn s Disease and Obesity or Overweight
NCT06937099 — crohn disease, obesity, overweight		Phase 3Recruiting2025
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight Phase 3b Study
NCT06937086 — colitis, obesity, therapeutics, overweight, colitis, ulcerative		Phase 3Recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS